Omeros (OMER) Expected to Announce Quarterly Earnings on Wednesday

Omeros (NASDAQ:OMER) is anticipated to post its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Omeros to post earnings of ($0.58) per share for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:30 PM ET.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Trading Up 0.2%

OMER stock opened at $6.59 on Monday. The firm has a 50 day simple moving average of $5.51 and a 200-day simple moving average of $4.57. The company has a market capitalization of $448.49 million, a P/E ratio of -3.12 and a beta of 2.40. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60.

Analysts Set New Price Targets

Several research analysts have weighed in on OMER shares. HC Wainwright raised their price objective on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Omeros by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock worth $13,723,000 after acquiring an additional 63,381 shares during the period. JPMorgan Chase & Co. lifted its position in Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in Omeros during the 2nd quarter valued at $32,000. Tower Research Capital LLC TRC increased its position in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Omeros by 548.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 21,376 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.